Santaris Pharma A/S Release: EPO Appeal Board Decides in Favor of the Wengel LNA Patent
4/18/2013 9:51:27 AM
More...
|
Santaris Pharma A/S Announces a Worldwide Discovery Alliance With Bristol-Myers Squibb Company (BMY) for Up to $100 Million
4/16/2013 7:07:12 AM
More...
|
Santaris Pharma A/S Release: USPTO Issues Inter Partes Reexamination Certificate of Key LNA Patent
4/5/2013 9:34:56 AM
More...
|
Research Published in The New England Journal of Medicine Demonstrates Marked and Long-Lasting Antiviral Activity Against HCV for Santaris Pharma A/S' Miravirsen, the First MicroRNA-Targeted Drug to Enter Clinical Trials
3/28/2013 8:51:39 AM
More...
|
Santaris Pharma A/S and miRagen Therapeutics Expand Worldwide Strategic Alliance to Discover and Develop LNA-Drugs Against Disease Causing Micrornas
1/8/2013 9:56:12 AM
More...
|
USPTO Grants Santaris Pharma A/S' Request for Inter-Partes Reexamination of Patent Licensed to Regulus Therapeutics, Inc.
1/7/2013 10:26:21 AM
More...
|
Court Focuses Patent Suit on Santaris Pharma A/S's Safe Harbor Defense
9/24/2012 10:45:04 AM
More...
|
Santaris Pharma A/S Presents Final Phase 2a Study Results for Miravirsen Showing Dose-Dependent, Prolonged Antiviral Activity in Hepatitis C Patients
4/19/2012 9:54:04 AM
More...
|
United States Patent and Trademark Office Upholds Key Santaris Pharma A/S LNA Patents in Two Re-Examination Cases Brought by Isis Pharmaceuticals, Inc. (ISIS)
11/30/2011 11:30:24 AM
More...
|
Santaris Pharma A/S Phase 2a Data of Miravirsen Shows Dose-Dependent, Prolonged Viral Reduction of 2-3 Logs HCV RNA After Four-Week Treatment in Hepatitis C Patients
11/7/2011 10:49:35 AM
More...
|
|